Nanoscintillation systems for aqueous-based liquid scintillation counting
    22.
    发明授权
    Nanoscintillation systems for aqueous-based liquid scintillation counting 失效
    用于水基液体闪烁计数的纳米沉淀系统

    公开(公告)号:US06855270B2

    公开(公告)日:2005-02-15

    申请号:US10165201

    申请日:2002-06-06

    摘要: The present invention relates to the use of nanoscintillation systems, or nanoparticles containing fluor molecules, that can be used to detect an electron-emitting or alpha-particle-emitting radioisotope in the absence of organic-solvents commonly used in organic-based liquid scintillation cocktails. The invention also relates to compositions and use of three oil-in-water microemulsion precursors that can be engineered rapidly, reproducibly, and cost-effectively to produce useful nanoparticles less than 100 nanometers.

    摘要翻译: 本发明涉及纳米振荡系统或含有氟分子的纳米颗粒的使用,其可用于在不存在通常用于有机液体闪烁鸡尾酒中的有机溶剂的情况下检测发射电子发射或α粒子的放射性同位素 。 本发明还涉及三种水包油微乳液前体的组合物和用途,其可以快速,可重复地和经济有效地工程化以制备小于100纳米的有用的纳米颗粒。

    Combination anti-leukemic therapy by utilizing suramin and biologic
response modifiers
    23.
    发明授权
    Combination anti-leukemic therapy by utilizing suramin and biologic response modifiers 失效
    通过利用苏拉明和生物反应调节剂组合抗白血病治疗

    公开(公告)号:US6121320A

    公开(公告)日:2000-09-19

    申请号:US31037

    申请日:1998-02-26

    申请人: Michael A. Doukas

    发明人: Michael A. Doukas

    CPC分类号: A61K31/38

    摘要: A method of treating leukemia which includes administering an effective amount of composition comprising suramin and a biological response modifier, wherein the suramin and the biological response modifier show synergistic or additive anti-leukemic activity. A pharmaceutical composition is also disclosed.

    摘要翻译: 一种治疗白血病的方法,其包括施用有效量的包含苏拉明和生物反应调节剂的组合物,其中所述苏拉明和生物反应调节剂显示出协同或添加的抗白血病活性。 还公开了药物组合物。

    Portocaval-right atrial shunt
    24.
    发明授权
    Portocaval-right atrial shunt 失效
    波尔卡瓦尔右心房分流

    公开(公告)号:US5879321A

    公开(公告)日:1999-03-09

    申请号:US787413

    申请日:1997-01-22

    申请人: Bradley B. Hill

    发明人: Bradley B. Hill

    IPC分类号: A61F2/06 A61M25/00 A61M5/00

    摘要: A shunt includes a tubular body having first and second legs at a proximal end and a third leg at a distal end. A fluid distensible balloon and cooperating insufflation conduit are carried on the tubular body. The first leg of the tubular body includes a longitudinal slit for receiving the second leg whereby the first and second legs may be positioned substantially coaxial so as to allow easier introduction of the shunt into the blood vessel of a patient. Similarly, the second leg having a longitudinally slit for receiving a portion of the cooperating insufflation conduit and also holding it in a coaxial position. A leader tube with a blunt atraumatic tip is received over the proximal end of the tubular body to further aid in the introduction of the shunt.

    摘要翻译: 分流器包括管状体,其在近端具有第一和第二腿部,在远端具有第三腿部。 流体膨胀气囊和配合吹气导管承载在管体上。 管状体的第一腿包括用于接纳第二腿的纵向狭缝,由此第一和第二腿可以基本上同轴地定位,以便容易地将分流器引入患者的血管。 类似地,第二腿具有用于接收协作的吹气管道的一部分并且还将其保持在同轴位置的纵向狭缝。 具有钝性无创尖端的引导管被容纳在管状体的近端上,以进一步有助于分流器的引入。

    Method of predicting optimum machining conditions
    25.
    发明授权
    Method of predicting optimum machining conditions 失效
    预测最佳加工条件的方法

    公开(公告)号:US5801963A

    公开(公告)日:1998-09-01

    申请号:US744907

    申请日:1996-11-08

    CPC分类号: G05B19/40938 Y02P90/265

    摘要: A computer implemented method for achieving optimum selection of machining parameters and tool inserts for finish turning operations is provided. The computer implemented method allows for the simultaneous consideration of the various machining performance criteria which are highly interactive and need to be taken into consideration when defining optimum cutting conditions or selecting optimum tool inserts for particular cutting conditions. The computer implemented method broadly includes the steps of (1) developing a process model for interrelating performance variables and process parameters for finish turning operations; (2) selecting one of the performance variables for optimization while maintaining the remaining performance variables and process parameters as constraints on the optimization process; and (3) applying non-linear programming techniques to the process model in order that optimum cutting conditions may be determined for a given tool insert or an optimum tool insert may be selected for given machining performance requirements.

    摘要翻译: 提供了一种用于实现最佳选择加工参数的计算机实现的方法和用于精加工操作的刀具刀片。 计算机实现的方法允许同时考虑高度交互的各种加工性能标准,并且在定义最佳切割条件或为特定切割条件选择最佳刀具刀片时需要考虑。 计算机实现的方法广泛地包括以下步骤:(1)开发用于完成车削操作的性能变量和过程参数相互关联的过程模型; (2)选择其中一个性能变量进行优化,同时将剩余的性能变量和过程参数作为优化过程的约束; 以及(3)将非线性规划技术应用于过程模型,以便可以针对给定的刀具刀片确定最佳切削条件,或者可以针对给定的加工性能要求选择最佳刀具刀片。

    Biodegradable microspheres as a carrier for macromolecules
    27.
    发明授权
    Biodegradable microspheres as a carrier for macromolecules 失效
    可生物降解的微球作为大分子的载体

    公开(公告)号:US5160745A

    公开(公告)日:1992-11-03

    申请号:US463008

    申请日:1990-01-09

    IPC分类号: A61K9/16

    摘要: A method for preparing biodegradable microspheres having a three-dimensional network in which biologically active macromolecular agents are physically entrapped therein. The microsphere is able to degrade and release the macromolecular agent at a controlled rate. The method involves emulsifying a vinyl derivative of a biodegradable hydrophilic polymer, a water-soluble monovinyl monomer and a biologically active macromolecule in water, and copolymerizing the biodegradable hydrophilic polymer and the water-soluble monovinyl monomer such that the biologically active macromolecule is entrapped therein.

    摘要翻译: 一种制备具有三维网络的可生物降解的微球的方法,其中生物活性大分子物质被物理捕获在其中。 微球能够以受控的速率降解和释放大分子试剂。 该方法包括将可生物降解的亲水聚合物的乙烯基衍生物,水溶性单乙烯基单体和生物活性大分子乳化在水中,并使生物降解的亲水聚合物和水溶性单乙烯基单体共聚,使生物活性大分子被捕获在其中。

    Triazoline anticonvulsant compounds and compositions
    29.
    发明授权
    Triazoline anticonvulsant compounds and compositions 失效
    三唑啉抗惊厥化合物和组合物

    公开(公告)号:US4689334A

    公开(公告)日:1987-08-25

    申请号:US856782

    申请日:1986-04-17

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    CPC分类号: C07D401/04 C07D249/06

    摘要: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, m-chloro-p-fluoro, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro, or p-COOR.sub.3, wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

    摘要翻译: 抗惊厥药组合物包含选自下组的化合物作为活性成分:其中R1是邻氯苯基,邻硝基苯基,2,4-或2,6-二氯苯基,4-吡啶基,3 吡啶基,2-吡啶基或2-喹啉基,R 2为氢,间或对三氟甲基,间氯代对氟,对甲基,对乙基,间或对氯,间硝基 ,对溴,对氟或对COOR 3,其中R 3是1至4个碳原子的低级烷基。 将组合物以提供约30mg / kg至300mg / kg的剂量的量施用于哺乳动物。

    Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants
    30.
    发明授权
    Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants 失效
    芳基取代的1H-4,5-二氢-1,2,3-三唑作为抗惊厥药

    公开(公告)号:US4618681A

    公开(公告)日:1986-10-21

    申请号:US629554

    申请日:1984-07-10

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    IPC分类号: C07D249/06 C07D401/04

    CPC分类号: C07D401/04 C07D249/06

    摘要: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, m-chloro-p-fluoro, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro, or p-COOR.sub.3, wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

    摘要翻译: 抗惊厥药组合物包含选自下组的化合物作为活性成分:其中R1是邻氯苯基,邻硝基苯基,2,4-或2,6-二氯苯基,4-吡啶基,3 吡啶基,2-吡啶基或2-喹啉基,R 2为氢,间或对三氟甲基,间氯代对氟,对甲基,对乙基,间或对氯,间硝基 ,对溴,对氟或对COOR 3,其中R 3是1至4个碳原子的低级烷基。 将组合物以提供约30mg / kg至300mg / kg的剂量的量施用于哺乳动物。